Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease

Shin,Youn‑Jeong; Jeon,Yeo  Jin; Jung,Namhee; Park,Joo‑Won; Park,Hae‑Young; Jung,Sung‑Chul

doi:10.3892/mmr.2015.4010

Substrate-specific gene expression profiles in different kidney cell types are associated with Fabry disease

Authors:
- Youn‑Jeong Shin
- Yeo Jin Jeon
- Namhee Jung
- Joo‑Won Park
- Hae‑Young Park
- Sung‑Chul Jung
View Affiliations

Affiliations: Department of Biochemistry, School of Medicine, Ewha Womans University, Seoul 158‑710, Republic of Korea
Published online on: July 1, 2015 https://doi.org/10.3892/mmr.2015.4010
Pages: 5049-5057
Copyright: © Shin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the gene encoding the α-galactosidase A (α-Gal A) lysosomal enzyme, which results in globotriaosylceramide (Gb3) storage in vascular endothelial cells and different cell types throughout the body. Involvement of the kidney and heart is life threatening, and fibrosis of these organs is considered to be involved in the pathogenesis of Fabry disease. An increased concentration of deacylated Gb3 (lyso‑Gb3) in the plasma of symptomatic patients has also been suggested as a causative molecular event. To elucidate the molecular mechanisms involved in renal fibrosis in Fabry disease, the present analyzed the changes in global gene expression prior to and following Gb3 or lyso‑Gb3 treatment in two types of kidney cell lines, human proximal renal tubular epithelial (HK‑2) and mouse renal glomerular mesangial (SV40 MES 13) cells. Gb3 and lyso‑Gb3 treatment regulated the expression of 199 and 328 genes in each cell type, demonstrating a >2.0‑fold change. The majority of the biological functions of the regulated genes were associated with fibrogenesis or epithelial‑mesenchymal transition (EMT). The gene expression patterns of sphingolipid‑treated HK‑2 cells were distinguishable from the patterns in the SV40 MES 13 cells. Several genes associated with the EMT were selected and evaluated further in kidney cells and in Fabry mouse kidney tissues. In the SV40 MES 13 cells, the DLL1, F8, and HOXA11 genes were downregulated, and FOXP2 was upregulated by treatment with Gb3 or lyso‑Gb3. In the HK‑2 cells, the ADAMTS6, BEST1, IL4, and MYH11 genes were upregulated. Upregulation of the FOXP2, COL15A1, IL4, and MYH11 genes was also observed in the Fabry mouse kidney tissues. The gene expression profiles in kidney cells following the addition of Gb3 or lyso‑Gb3 revealed substrate‑specific and cell‑specific patterns. These findings suggested that Gb3 and lyso‑Gb3 lead to renal fibrosis in Fabry disease through different biochemical modulations.

View Figures

View References

1	Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL and Laster L: Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med. 276:1163–1167. 1967. View Article : Google Scholar : PubMed/NCBI
2	Kint JA: The enzyme defect in Fabry's disease. Nature. 227:11731970. View Article : Google Scholar : PubMed/NCBI
3	Densick RJ, Ioannou YA and Eng CM: Alpha-galactosidase A deficiency: Fabry disease. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. Scriver CR, Beaudet AL, Sly WS and Valle D: McGraw-Hill; New York: pp. 3733–3774. 2001
4	Weidemann F, Sanchez-Niño MD, Politei J, Oliveira JP, Wanner C, Warnock DG and Ortiz A: Fibrosis: A key feature of Fabry disease with potential therapeutic implications. Orphanet J Rare Dis. 8:1162013. View Article : Google Scholar : PubMed/NCBI
5	Aerts JM, Groener JE, Kuiper S, Donker-Koopman WE, Strijland A, Ottenhoff R, van Roomen C, Mirzaian M, Wijburg FA, Linthorst GE, et al: Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci USA. 105:2812–2817. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sanchez-Niño MD, Sanz AB, Carrasco S, Saleem MA, Mathieson PW, Valdivielso JM, Ruiz-Ortega M, Egido J and Ortiz A: Globotriaosylsphingosine actions on human glomerular podocytes: Implications for Fabry nephropathy. Nephrol Dial Transplant. 26:1797–1802. 2011. View Article : Google Scholar
7	Campanholle G, Ligresti G, Gharib SA and Duffield JS: Cellular mechanisms of tissue fibrosis. 3. Novel mechanisms of kidney fibrosis. Am J Physiol Cell Physiol. 304:C591–C603. 2013. View Article : Google Scholar : PubMed/NCBI
8	Iredale JP: Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 117:539–548. 2007. View Article : Google Scholar : PubMed/NCBI
9	Zeisberg M and Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol. 21:1819–1834. 2010. View Article : Google Scholar : PubMed/NCBI
10	Iwano M, Plieth D, Danoff TM, Xue C, Okada H and Neilson EG: Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest. 110:341–350. 2002. View Article : Google Scholar : PubMed/NCBI
11	Zeisberg EM, Potenta SE, Sugimoto H, Zeisberg M and Kalluri R: Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J Am Soc Nephrol. 19:2282–2287. 2008. View Article : Google Scholar : PubMed/NCBI
12	Ohshima T, Murray GJ, Swaim WD, Longenecker G, Quirk JM, Cardarelli CO, Sugimoto Y, Pastan I, Gottesman MM, Brady RO, et al: α-Galactosidase A deficient mice: a model of Fabry disease. Proc. Natl Acad Sci USA. 94:2540–2544. 1997. View Article : Google Scholar
13	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011
14	Schefe JH, Lehmann KE, Buschmann IR, Unger T and Funke-Kaiser H: Quantitative real-time RT-PCR data analysis: Current concepts and the novel “gene expression's CT difference” formula. J Mol Med. 84:901–910. 2006. View Article : Google Scholar
15	Gubler MC, Lenoir G, Grünfeld JP, Ulmann A, Droz D and Habib R: Early renal changes in hemizygous and heterozygous patients with Fabry's disease. Kidney Int. 13:223–235. 1978. View Article : Google Scholar : PubMed/NCBI
16	Fogo AB, Bostad L, Svarstad E, Cook WJ, Moll S, Barbey F, Geldenhuys L, West M, Ferluga D, Vujkovac B, et al: Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN). Nephrol Dial Transplant. 25:2168–2177. 2010. View Article : Google Scholar :
17	Konopka G, Bomar JM, Winden K, Coppola G, Jonsson ZO, Gao F, Peng S, Preuss TM, Wohlschlegel JA and Geschwind DH: Human-specific transcriptional regulation of CNS development genes by FOXP2. Nature. 462:213–217. 2009. View Article : Google Scholar : PubMed/NCBI
18	Hägg PM, Hägg PO, Peltonen S, Autio-Harmainen H and Pihlajaniemi T: Location of type XV collagen in human tissues and its accumulation in the interstitial matrix of the fibrotic kidney. Am J Pathol. 150:2075–2086. 1997.PubMed/NCBI
19	Furusu A, Miyazaki M, Koji T, Abe K, Ozono Y, Harada T, Nakane PK, Hara K and Kohno S: Involvement of IL-4 in human glomerulonephritis: an in situ hybridization study of IL-4 mRNA and IL-4 receptor mRNA. J Am Soc Nephrol. 8:730–741. 1997.PubMed/NCBI
20	Rüger BM, Hasan Q, Erb KJ and Davis PF: Progression of renal disease in interleukin-4 transgenic mice: involvement of transforming growth factor-beta. Int J Exp Pathol. 80:113–123. 1999. View Article : Google Scholar : PubMed/NCBI
21	Renard M, Callewaert B, Baetens M, Campens L, MacDermot K, Fryns JP, Bonduelle M, Dietz HC, Gaspar IM, Cavaco D, et al: Novel MYH11 and ACTA2 mutations reveal a role for enhanced TGFβ signaling in FTAAD. Int J Cardiol. 165:314–321. 2011. View Article : Google Scholar
22	Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, Gosden C, Bard J, Buckler A, Pelletier J and Housman D: The candidate Wilms' tumour gene is involved in genitourinary development. Nature. 346:194–197. 1990. View Article : Google Scholar : PubMed/NCBI
23	Buckler AJ, Pelletier J, Haber DA, Glaser T and Housman DE: Isolation, characterization and expression of the murine Wilms' tumor gene (WT1) during kidney development. Mol Cell Biol. 11:1707–1712. 1991.PubMed/NCBI
24	Grubb GR, Yun K, Williams BR, Eccles MR and Reeve AE: Expression of WT1 protein in fetal kidneys and Wilms tumors. Lab Invest. 71:472–479. 1994.PubMed/NCBI
25	Brunskill EW and Potter SS: Changes in the gene expression programs of renal mesangial cells during diabetic nephropathy. BMC Nephrol. 13:702012. View Article : Google Scholar : PubMed/NCBI
26	Mrowka C and Schedl A: Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features. J Am Soc Nephrol. 11(Suppl 16): S106–S115. 2000.PubMed/NCBI
27	Hills CE and Squires PE: The role of TGF-β and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev. 22:131–139. 2011.PubMed/NCBI